Hematological malignancies and pregnancy:: A final report of 84 children who received chemotherapy in utero
Hematological malignancies and pregnancy:: A final report of 84 children who received chemotherapy in utero
复制标题
DOI：
10.3816/clm.2001.n.023
复制
发表时间：
2001-12-01
期刊：
影响因子：
--
通讯作者：
Neri, N
中科院分区：
文献类型：
--
作者：
Avilés, A;Neri, N
为了评估母亲在怀孕期间接受化疗治疗血液系统恶性肿瘤的儿童发生急性和晚期副作用的风险，我们对84名儿童进行了长期随访分析。我们研究中的84名儿童的母亲患有血液恶性肿瘤（29例急性白血病，26例霍奇金病和29例恶性淋巴瘤），在怀孕期间接受化疗，其中38例在妊娠早期。对这些儿童进行身体健康、生长、发育、血液学、细胞遗传学、神经学、心理学和学习障碍检查。还考虑了这些儿童中癌症或急性白血病的发生。其中一些患者已经成为父母，他们的孩子也被纳入本分析。在所有研究的儿童中，包括12名第二基因组儿童，出生体重正常;学习和教育表现正常;没有观察到先天性，神经或心理异常。中位随访时间为18.7年（范围：6-29年），未观察到癌症或急性白血病。这些结果证实了我们以前的报告，这表明，如果一个怀孕的病人有一个积极的血液恶性肿瘤，化疗在全剂量可以安全地管理，即使在第一个三个月，如果治愈的血液恶性肿瘤被认为是合理的。
To evaluate the risk of acute and late side effects in children whose mothers received chemotherapy during pregnancy for hematological malignancies, we performed an analysis of 84 children with a long-term follow-up. The 84 children in our study were born to mothers with hematological malignancies (29 acute leukemia, 26 Hodgkin's disease, and 29 malignant lymphoma) who received chemotherapy during pregnancy, including 38 during the first trimester. These children were examined for physical health; growth; development; and hematological, cytogenetic, neurological, psychological, and learning disorders. The occurrence of cancer or acute leukemia in these children was also considered. Some of these patients have become parents, and their children were also considered in this analysis. In all of the children studied, including the 12 second-gene ration children, the birth weight was normal; learning and educational performance were normal; and no congenital, neurological, or psychological abnormalities were observed. With a median follow-up of 18.7 years (range, 6-29 years), no cancer or acute leukemia has been observed. These results confirm our previous reports, suggesting that if a pregnant patient has an aggressive hematological malignancy, chemotherapy at full doses can be safely administered, even during the first trimester, if cure of the hematological malignancy is considered reasonable.